Greed and Capitalism

What kind of society isn't structured on greed? The problem of social organization is how to set up an arrangement under which greed will do the least harm; capitalism is that kind of a system.
- Milton Friedman

Thursday, March 28, 2013

Solar Batteries

Solar batteries could be utilities' next headache

FRANKFURT/MILAN (Reuters) - Renewable energy (NasdaqGS: REGI - news) is constantly evolving and challenging traditional utilities but one growing sector could make home-generated power much easier to use and cut customers' dependence on energy companies dramatically - solar batteries.

A major conundrum with solar panels has always been:
 how to keep the lights on when the sun isn't shining.

Solar batteries allow homes and businesses to store solar power to use in the hours of darkness and can also help to create "smart grids" that react to sudden power swings and free stored energy when needed.

The technology is still expensive and not widely used but with energy bills soaring for consumers, it could quickly gain market share and reduce dependence on utilities, which are already struggling with overcapacity and weak demand.

Italy has some of the highest power prices in Europe and is looking at how to cut costs to allow its businesses to compete.

Nicola Cosciani, head of energy storage at Italy's top industrial battery maker Fiamm, says heavy power users like cement and steel makers are looking at generating and storing their own solar power - and even selling excess power from their batteries on to the grid.

"Germany and Italy will be explosive markets for residential storage and big energy users are also starting to show an interest. This is a game changer," he told Reuters.

By 2020, the EU aims to get 20 percent of its energy from renewables. That compares to 12.5 percent of the EU energy mix in 2010 and 8.1 percent in 2004, according to most recent EU statistics. Batteries will be crucial in reaching this target.

In Germany, the world's largest solar market and Europe's largest energy consumer, about 40 percent of all modules sold have been installed in homes, directly hitting demand for power  from E.ON and RWE (Xetra: 703712 - news) .

A four-person household can cut the amount of power it uses from the grid by 30 percent per year if it uses solar panels and another 30 percent if it uses a solar battery, leaving it to buy only 40 percent of supplies from utilities.

With power bills rising and solar subsidies and battery prices falling, power storage is expected to expand dramatically within the next 2-4 years.


PRICE FALLS

Solar batteries look like a large car battery and are usually installed in the basement of a house, hooked up to a solar panel outside and on to the grid with an inverter.

That allows the batteries to charge up and store excess energy during the day and release it in the evening. They can also release surplus energy on to the grid.

The kit is still expensive but the price of solar panels has already dropped two thirds in the last two years and the price of batteries is expected to halve in the next few years.

A single solar battery costs about 800 euros per kilowatt hour (kWh), so an average 6kWh battery costs about 5,000 euros (4,324 pounds).

Including installation, tax and components to connect it to the grid, an average household - which consumes 3,500 kWh per year - would pay about 10,000-20,000 euros per storage system.

"We believe that lithium batteries will be available for 400-500 euros per kilowatt hour (kWh) in a few years, featuring a lifespan of 20 years," said Martin Rothert, product manager at SMA Solar, Germany's largest solar company.

Solar batteries use either lead-acid or lithium-ion.

Germany plans to support the installation of solar batteries with at least 50 million euros in credit lines which will also support a greater roll-out.

Italian energy consultant BIP said the battery market will reach at least 9,000 megawatts (MW) of capacity by 2020 from today's 270 MW.

"Due to rising supply and awareness, we expect several tens of thousands of these systems to be sold in Germany this year," said Norbert Hahn, board member at IBC Solar.


Batteries are also needed to develop smart grids, which adjust power supply to satisfy demand across the network.

Seeing the writing on the wall for traditional generation and distribution, Italian utility Enel (Milan: ENEL.MI - news) has done a deal with Japan's NEC - one of the world's leading energy storage system makers - to roll out new generation smart grids.

Developing smart grids can help cut costs and allow independent renewable energy providers to sell their power into the grid. Renewable energy, once capital costs are amortised, is cheaper and more secure.

"The idea is to apply the same principles of the Internet to electricity networks - any device hooked up can send and receive content," said Ugo Govigli, vice president for European smart grid solutions for NEC Italia.

(Additional reporting by Paul Arnold in Zurich; editing by Jane Barrett)




 Source:  http://news.yahoo.com/solar-batteries-could-utilities-next-101729309.html




Sustainable Energy Technologies Raises $500,000

 

 

Sustainable Energy Technologies Raises $500K

 
Posted on: March 27, 2013
 
 

Sustainable Energy Technologies, a Calgary-based designer, manufacturer and distributor of power inverters for grid-connected solar PV systems, announced that it has received a C$500K investment from UK-based Doughty Hanson Technology Ventures.

Doughty Hanson has been investing in Sustainable Energy Technologies since 2009.

PRESS RELEASE:

Sustainable Energy Technologies Ltd (TSX VENTURE:STG) (“Sustainable Energy” or the “Company”) is pleased to announce that Doughty Hanson Technology Ventures (“DHTV”) will invest $500,000 to enable the Company to accelerate production of its energy storage inverters for German solar battery systems. The inverters will be delivered under a previously announced multi-year deal with a leading European developer of solar battery systems (News Release dated February 19, 2013).

George Powlick, Managing Director of DHTV commented: “Sustainable Energy’s inverter is a natural fit for the energy storage market with distinct efficiency, cost and integration advantages that make it compelling. We believe this market presents a large opportunity for the Company and we continue to work with management to help make it a reality.”

Solar batteries enable homes and businesses to store solar power for use during peak demand periods reducing demands on the power grid and helping to create “smart grids” that can react to sudden power swings and free up stored energy when needed. Sustainable Energy’s energy storage inverters manage the connection of the battery to the power grid and to the homeowner, seamlessly transitioning from charging to discharging the batteries to optimize the use of the solar energy.

Germany and Italy will be explosive markets for residential storage; and expectations are for tens of thousands of systems to be installed in Germany alone this year with as many as 9,000 MW to be installed in Europe alone over the next 6 years according to industry experts.

(See: Solar Batteries Could be Utilities Next Headache; Reuters, March 8 2013: http://news.yahoo.com/solar-batteries-could-utilities-next-101729309.html)

Depending on power ratings and the energy storage required up to 3 energy storage inverters are typically included in each solar battery system. Sustainable Energy is forecasting delivery of a minimum 10,000 inverters to Germany over the next 30 months with the potential for more than double that amount over the same period.

“We are very excited about our partnership in Europe and we have had engagement from multiple large players in this energy storage sector over the past 10 – 12 weeks for this and other applications. The investment by Doughty Hanson is strong validation of the significant value of our patented technology and the strategy we are executing.” commented Michael Carten CEO of the Company

The Convertible Debenture is unsecured, bears interest at 8% per annum, and is convertible into 50,000, $10, 8% First Preferred Shares (“Preferred Shares”) of Sustainable Energy. The Preferred Shares are themselves convertible into common shares of the Company at a price of $0.105 per share. The term of the Debenture is for a period of 6 months enabling the Company to secure longer term financing for its business. DHTV has a pre-emptive right to participate in up to $1 million of such a financing alongside outside investors and management, including the option of tendering the Convertible Debenture as payment.

As additional consideration the Company will issue detachable common share purchase warrants to acquire up to 4,750,000 common shares of the Company at an exercise price of $0.105. This financing remains subject to TSX Venture Exchange approval.
The Company also announced that the Company has issued $114,000 3% Secured Debentures to the CEO of the Company on terms identical to the previously announced (See News Release dated June 29, 2012) issue of 800,00 3% 5 yr Royalty Debentures. Subject to approval of the TSX Venture Exchange the Company will also issue 39,900 bonus shares at a nominal price of $0.50 per share.



About Sustainable Energy:

Sustainable Energy (www.SustainableEnergy.com) designs and manufactures intelligent power inverters for a wide arrange of distributed generation and storage technologies. The inverters incorporate patented breakthrough technologies which enable the highest efficiency conversion of low voltage direct current inputs in the industry.

A single standard low cost electronics platform supports (i) the solar industry’s only industry standard inverter enabling the higher yields and installation flexibility; the solar industry’s only industry standard inverter enabling the safety of extra low operating voltages and (iii) the industry’s highest bi-directional power conversion efficiencies for grid tied energy storage and fuel cells.

Approximately 20MW of 1st and 2nd generation PARALEX inverters have been installed in 7 different countries.

Contact Information:

Sustainable Energy Technologies Ltd.
Michael Carten
Chief Executive Officer
403.508.7177 #111
Michael.Carten@sustainableenergy.com

Photo courtesy of Shutterstock.


 Tags: ,


 Source:
 http://www.pehub.com/193135/sustainable-energy-technologies-raises-500k/


 


News

Doughty Hanson Completes Restructuring
08/02/2013
 
Doughty Hanson, one of the largest independent private equity firms in Europe, today announced its intention to focus on its private equity business following the creation of a new partnership structure.

After the death of co-founder and majority shareholder Nigel Doughty in February 2012, Dick Hanson has resumed his role as Head of Private Equity and Executive Chairman. 
He has conducted a review of the overall business to ensure it is best positioned to continue to deliver outstanding returns to the investors in its funds.  As a result of this review, the Firm will focus on its core business of private equity.  No future funds will be raised for its Real Estate or Technology Ventures businesses.

Members of the Real Estate team will continue to manage Real Estate Fund II as before. Members of the Technology Ventures team will continue to invest Technology Ventures II and manage the Technology Ventures portfolio.

Doughty Hanson CEO, Stephen Marquardt, said:  
“We have spent considerable time speaking with our investors and reflecting on the future of the business.  While we have had notable successes in both Real Estate and Technology Ventures, the real heritage of Doughty Hanson lies in its private equity business, where we have an outstanding track record.  Following the creation of a partnership structure for the private equity business, today’s announcement is a logical step and in the best interests of our investors, the firm and its many stakeholders.”

"We are not planning to make changes to our Real Estate or Technology Ventures teams, which will continue to manage their existing funds as before and will focus on generating returns for our investors.  However, we will not be establishing any new funds in these sectors.”

For over 25 years, Doughty Hanson has had a history of creating value, investing responsibly and generating superior returns for its Limited Partner investors.  

Recent transactions have included 
-the acquisition of QuirĂ³n/USP Hospitales, one of the largest private hospital operators in Spain; 
-  Eurofiber, a major fibre optic company in the Netherlands; and in Germany, 
- the public-to-private acquisition of CinemaxX by Vue Entertainment.  

Recent realisations have included 
- the successful IPO of Tumi (a Private Equity Fund IV portfolio company) on the NYSE in April 2012, as well as 
- a secondary public offering in November 2012, and
- the sale of Norit (a Private Equity Fund V portfolio company) which was announced in June 2012.




Wednesday, March 27, 2013

Biogen blockbuster drug approved by FDA


Biogen Gains U.S. Approval to Sell Its First Pill for MS

Biogen Idec Inc. (BIIB), the maker of multiple sclerosis drugs Avonex and Tysabri, won U.S. approval for its first pill for the disease, Tecfidera, a medicine analysts project will dominate the MS market.

The drug, formerly known as BG-12, may generate $3.25 billion in annual revenue by 2017 for the Weston, Massachusetts-based company, according to the average of eight analysts’ estimates compiled by Bloomberg. 



Clinical Trials

The approval was announced by the Food and Drug Administration today in a statement. The drug is recommended to be taken twice a day and Biogen will make Tecfidera available to patients in the U.S. in the coming days, the company said in a statement. 

Tecfidera was shown in two studies to reduce patients’ annual relapse rate by 49 percent when given either twice a day or three times a day. It cut the proportion of patients who relapsed by 43 percent at twice-daily dosing and 47 percent at three times daily compared with placebo. 

Side effects were similar across the placebo and treatment groups, with the most common adverse events associated with Tecfidera being flushing and gastrointestinal effects, according to the company. 

The FDA recommended that a patient’s white blood cell count be assessed before starting treatment with the pill. While the medicine may decrease these infection-fighting cells, no significant increase in infections was seen in patients taking Tecfidera in clinical trials, the agency said in its statement. 

“Relative to other MS drugs, such as Tysabri and Gilenya, this basic test is a much less invasive requirement,Andrew Berens, an analyst with Bloomberg Industries, wrote today in a research note. 




Biogen Stock Price:  

 The shares rose to their highest price ever.

Biogen shares rose 3.2 percent to $182.68 at the close in New York, the highest price since the stock was first offered to the public in September 1991. The company has gained 45 percent in the last 12 months and doubled since April 2011 when Biogen first reported positive data from a late-stage trial of Tecfidera. 




Competitors  

Tecfidera follows Novartis AG (NOVN)’s Gilenya and Sanofi (SAN)’s Aubagio to the market as oral options for MS, a central nervous system disease otherwise treated by injection or infusion. 

The drug was recommended for marketing approval by European Union health regulators on March 22, the same day as Paris-based Sanofi’s Aubagio, another oral option for MS. Aubagio already is approved in the U.S. 
Though Sanofi’s drug Aubagio has the advantage of being a pill, its “efficacy profile is not that impressive versus other oral compounds,” Asthika Goonewardene, an analyst for Bloomberg Industries in London, said in a telephone interview. Analysts estimate the medicine will have 2017 sales of 718 million euros ($917 million). 

Basel, Switzerland-based Novartis’s Gilenya, the first oral treatment approved for MS, has safety issues that hamper its widespread use. U.S. and European regulators placed new safety precautions on the drug’s use last year after a three-month review triggered by the deaths of 15 patients. Doctors shouldn’t prescribe Gilenya to patients with a history of cardiovascular and cerebrovascular disease or who take heart-rate lowering medication, regulators said. Analysts expect 2017 revenue of $2.7 billion, according to the average of 10 estimates compiled by Bloomberg. 



Summary: Tecfidera

“With the FDA approval of Tecfidera, we will offer the MS community a treatment with strong efficacy and a favorable safety profile in the convenience of a pill -– a combination we believe will have a significant positive impact on the way people live with this chronic disease,” Biogen Chief Executive Officer George Scangos said in the company’s statement.

“We believe Tecfidera will raise expectations for what people living with MS can achieve with their therapy.” 

The drug may be priced at $50,000 to $55,000 a year, lower than Gilenya at $58,000 and higher than Aubagio at $45,000, said Michael Yee, an RBC Capital Markets analyst in San Francisco. 

“We believe this is an attractive level of pricing given Tecfidera’s combined efficacy and safety profile,” he wrote today in a research note. 
 
Because of its efficacy, safety and dosing convenience, Tecfidera may gain as much as 20 percent of the market in its first year, Cowen & Co. analyst Eric Schmidt projects.

“It really is going to be a great addition to the toolbox,” Timothy Coetzee, chief research officer of the National Multiple Sclerosis Society, said in an interview before the approval was announced. “There seems to be quite a lot of patient awareness about it.

Tuesday, March 26, 2013

New M.S. Drug


Decision Looms on New Multiple Sclerosis Drug

Will good news from Europe echo on this side of the Atlantic within the next few days?

Biogen Idec (NASDAQ: BIIB  ) is certainly hoping so.

The biotech's multiple sclerosis drug Tecfidera received a positive recommendation for market authorization approval from the European Union's Committee for Medicinal Products for Human Use, or CHMP, last Friday. 

Next up for Tecfidera is a decision by the U.S. Food and Drug Administration due this week. A final decision in Europe will come in the next two months.

Many in the MS community are anxiously awaiting availability of Tecfidera. What's behind the buzz -- and how likely is it that the MS drug will gain approval?

Disrupting the market?

While there is no cure, several treatments are currently available for slowing the progression of multiple sclerosis.  Beta interferon drugs help prevent damage to myelin, a sheath that shields nerve fibers. Leading beta interferon drugs are Biogen's Avonex, Betaseron from Bayer, and Rebif, which is co-marketed by EMD Serona and Pfizer (NYSE: PFE  ) . All three drugs are administered through injection. Common side effects include inflammation at the injection site and flu-like symptoms.

Teva Pharmaceuticals' (NYSE: TEVA  ) Copaxone also works by protecting myelin. Like the beta interferon drugs, Copaxone is taken via injection with one of the most common side effects relating to inflammation at the site of injection. 

Another treatment that has demonstrated success with slowing progression of MS is Tysabri. Biogen and Elan Pharmaceuticals (NYSE: ELN  ) co-market the drug for now, but the two companies recently announced a deal where Biogen would buy full rights for Tysabri for $3.25 billion. Similar to the other drugs already mentioned, Tysabri is administered through injection. It has some of the same kinds of side effects as the others, but also can increase the possibility of patients getting a rare brain infection that can lead to death or severe disability.

The inconvenience and possibility of reactions associated with these injections opened the door for commercial success of drugs that can be taken orally. Novartis' (NYSE: NVS  ) Gilenya was the first MS pill to gain FDA approval in 2010. Gilenya racked up 2012 sales of $1.2 billion. However, sales were dampened somewhat in early 2012 after the FDA and the European Medicines Agency announced investigations of several deaths related to heart problems in patients taking Gilenya.  

Last September, the FDA approved another oral treatment for MS -- Sanofi's Aubagio. Sanofi received good news from Europe at the same time as Biogen, getting a positive recommendation from CHMP for Aubagio last week.

However, many expect Tecfidera to become the biggest seller in the MS market with annual sales topping $3.25 billion within the next four years. With all of the treatments already available, why is there such eagerness for Biogen's new drug? Three reasons stand out.

First, like Gilenya and Aubagio, Tecfidera is a pill and therefore won't have the inconvenience and injection site reactions associated with most of the other available drugs.

Second, the drug has demonstrated solid efficacy  -- reducing patients' annual relapse rate by nearly half.

Third, Tecfidera's safety profile looks to be better than the others, with the most common side effects including flushing and gastrointestinal effects such as nausea and diarrhea. Biogen hopes that the drug's convenience, efficacy, and safety will score big with patients and prescribers.


Cart before the horse?

Is all this talk getting the cart before the horse, though? Tecfidera still hasn't been approved either in the U.S. or Europe. The FDA delayed its decision on the drug by three months back in October to "allow additional time for review of the application." Murphy's Law has raised its ugly head before with promising drugs.

Like most observers, I don't expect there will be any roadblocks with approval for Tecfidera either in the U.S. or in Europe. CHMP's positive recommendation last week was definitely a good sign. The FDA delay was a standard extension and not particularly unusual. The agency didn't ask for any additional information from Biogen, so no new concerns were raised about Tecfidera's chances of approval.

Anything can happen with regulatory approval processes, but I look for more good news for Biogen this week. I also expect that Tecfidera will live up to the high expectations held by many. The drug should be a great addition to Biogen's already-strong MS portfolio. The cart might still be in front of the horse for now, but I suspect that we'll see plenty of horsepower from Biogen and Tecfidera over the years to come.





Source:  http://www.fool.com/investing/general/2013/03/25/decision-looms-on-new-multiple-sclerosis-drug.aspx



Wednesday, March 20, 2013

Lawrence Cunningham on the Essays of Warren Buffett



loaded on Mar 17, 2013

 
Great ideas: http://manualofideas.com
Great events: http://valueconferences.com
Great investors: http://greatinvestors.tv and http://undiscoveredpm.com

Great ideas are the lifeblood of the investment business and the exclusive focus of The Manual of Ideas. Leading value investors use The Manual of Ideas in their idea generation processes. The Manual of Ideas sets a new standard by delivering timely, differentiated value investing ideas in a clear, concise manner. The Manual of Ideas is authored by equity research professionals who have grown up on the teachings of Ben Graham, Warren Buffett and Joel Greenblatt, and have studied under luminaries such as Yale CIO David Swensen and Economics Nobel Laureate James Tobin.

Monday, March 18, 2013

Quotes: Money and Markets





"Rule No.1: Never lose money. Rule No.2: Never forget rule No.1. " - Warren Buffett


 "Risk comes from not knowing what you are doing." – Warren Buffett


 
"In the business world, the rearview mirror is always clearer than the windshield." - Warren Buffett

 
"Most investors want to do today what they should have done yesterday." -Larry Summers


 "Bottoms in the investment world don’t end with four-year lows, they end with 10 or 15-year lows." – Jim Rogers


 
"Columbus did not seek a new route to the Indies in response to a majority directive." -Milton Friedman


 
"Well, you know, I was a human being before I became a businessman." - G Soros


 
"Men of means look at making money as a game which they love to play." – J. Paul Getty

 
"Seek advice on risk from the wealthy who still take risks, not friends who dare nothing more than a football bet." – J. Paul Getty

 
"Seek advice on risk from the wealthy who still take risks, not friends who dare nothing more than a football bet." – J. Paul Getty


"Markets can remain irrational longer than you can remain solvent." -John Maynard Keynes


 
"The stock market is filled with individuals who know the price of everything, but the value of nothing." - Phillip Fisher


 
"When everything seems to be going against you, remember that the airplane takes off against the wind, not with it." – Henry Ford


"The four most dangerous words in investing are: 'this time it's different.'" - Sir John Templeton


 "Money was never a big motivation for me, except as a way to keep score. The real excitement is playing the game" - Donald Trump

 
"Diversification is a hedge for ignorance" - William O’Neil.


 
"Cash is a fact, profit is an opinion." -Alfred Rappaport

 
"I would not pre-pay. I would invest instead and let the investments cover it." - Dave Ramsey


 
"So you think that money is the root of all evil. Have you ever asked what is the root of all money?" -Ayn Rand


 
"When I was young I thought that money was the most important thing in life; now that I am old I know that it is." -Oscar Wilde



 "I don't like money, actually, but it quiets my nerves." -Joe Louis


 
"I would not pre-pay. I would invest instead and let the investments cover it." - Dave Ramsey


 
"When buying shares, ask yourself, would you buy the whole company?" - Rene Rivkin (Net Worth $346 Million)



 
"Bottoms in the investment world don’t end with four-year lows, they end with 10 or 15-year lows." – Jim Rogers


 
"Budget: a mathematical confirmation of your suspicions." -A.A. Latimer

 
"Literature is an investment of genius which pays dividends to all subsequent times." - John Burroughs


 
"Any informed borrower is simply less vulnerable to fraud and abuse." - Alan Greenspan



 
"How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case." - Robert G. Allen


 "Stock market bubbles don't grow out of thin air. They have a solid basis in reality, but realty as distorted by a misconception" - G. Soros


 
"Markets can remain irrational longer than you can remain solvent." -John Maynard Keynes


 
"You must not only learn to live with tension, you must seek it out. You must learn to thrive on stress." – J. Paul Getty


 
"My basic advise is don’t lose money" - Jim Rogers



 "Markets are constantly in a state of uncertainty and flux and $ is made by discounting the obvious and betting on the unexpected. " - Soros


 
"Cash is a fact, profit is an opinion." -Alfred Rappaport


 
"The men who have succeeded are men who have chosen one line and stuck to it." – Andrew Carnegie



 "Any informed borrower is simply less vulnerable to fraud and abuse." - Alan Greenspan


 
"I haven’t met a rich technician" - Jim Rogers


 
"Go to the mouse you foolish investor and learn. A mouse never entrusts its life to only one hole." – Ajaero Tony Martins


 
"Old men are prone to invest the futures of young men with their own past sorrows." - Horore de Balzac


 "A business that makes nothing but money is a poor business." -Henry Ford
  

"If you want to have a better performance than the crowd, you must do things differently from the crowd. " - J. Templeton



 
"Historically, there has been a bull market in the commodities every 20 or 30 years." – Jim Rogers


 "Don’t try to buy at the bottom or sell at the top" – Bernard Baruch


 
"Men of means look at making money as a game which they love to play." – J. Paul Getty


 "An investment in knowledge pays the best interest." - Benjamin Franklin


 “The time of maximum pessimism is the best time to buy and the time of maximum optimism is the best time to sell.” - John Templeton


 "I will tell you how to become rich. Close the doors. Be fearful when others are greedy. Be greedy when others are fearful." -Warren Buffett


 
"We simply attempt to be fearful when others are greedy and to be greedy only when others are fearful." -Warren Buffett




 
"The key to making money in stocks is not to get scared out of them." - Peter Lynch


"Time is your friend; impulse is your enemy. " Jack Bogie


 
"Only buy something that you'd be perfectly happy to hold if the market shut down for ten years." - Warren Buffett



 
"Those with the enterprise lack the money and those with the money lack the enterprise to buy stocks when they are cheap." -Benjamin Graham



 
"Wall Street is the only place that people ride to in a Rolls Royce to get advice from those who take the subway." - Warren Buffett


 
"In the business world, the rearview mirror is always clearer than the windshield." - Warren Buffett


 "Put not your trust in money, but put your money in trust." - Oliver Wendell Holmes



 
"Maybe the trend is your friend for a few minutes in Chicago, but for the most part it is rarely a way to get rich" - Jim Rogers.


 
"Do you know the only thing that gives me pleasure? It’s to see my dividends coming in." – John D. Rockefeller


 "Never invest in anything that eats or needs painting." - Billy Rose

 
"At a certain point, money is meaningless. It ceases to be the goal. The game is what counts." – Aristotle Onassis


 
"Go for a business any idiot can run because sooner or later, any idiot probably is going to run it." – Peter Lynch



 
"Although it’s easy to forget sometimes, a share is not a lottery ticket. It’s part ownership of a business." – Peter Lynch



 
"So you think that money is the root of all evil. Have you ever asked what is the root of all money?" -Ayn Rand


 
"Know what you own, and know why you own it." - Peter Lynch


 "Even a mistake may turn out to be the one thing necessary to a worthwhile achievement.” – Henry Ford




"Invest in yourself. Your career is the engine of your wealth." - Paul Clitheroe




 
"When everything seems to be going against you, remember that the airplane takes off against the wind, not with it." – Henry Ford


 
"Wide diversification is only required when investors do not understand what they are doing." - Warren Buffett


 
"In this business if you're good, you're right six times out of ten. You're never going to be right nine times out of ten." - Peter Lynch

 "The business schools reward difficult complex behavior more than simple behavior, but simple behavior is more effective." - Warren Buffett


 "Those with the enterprise lack the money and those with the money lack the enterprise to buy stocks when they are cheap." -Benjamin Graham


 
"The four most dangerous words in investing are 'This time it's different'." - John Templeton


"It’s never too late to learn." – Malcolm Forbes

 
”I’m only rich because I know when I’m wrong…I basically have survived by recognizing my mistakes.” - George Soros



 
"Financial leverage is the advantage the rich have over the poor and middle class." – Rich Dad



 "Money is better than poverty, if only for financial reasons." - Woody Allen



 "A market is the combined behavior of thousands of people responding to information, misinformation and whim." - Kenneth Chang


 
"Index investing outperforms active management year after year." – Jim Rogers



 "Wall Street people learn nothing and forget everything." - Ben  Graham


 
"Seek advice on risk from the wealthy who still take risks, not friends who dare nothing more than a football bet." – J. Paul Getty


 
"An investment in knowledge pays the best interest." - Benjamin Franklin



 
"Money was never a big motivation for me, except as a way to keep score. The real excitement is playing the game" - Donald Trump


 
"Look at market fluctuations as your friend rather than your enemy. Profit from folly rather than participate in it." – Warren Buffett



 
"Money can't buy you happiness but it does bring you a more pleasant form of misery." - Spike Milligan




 
"When I was young I thought that money was the most important thing in life; now that I am old I know that it is." -Oscar Wilde




 
"Diversify your investments." - John Templeton



 "The time of maximum pessimism is the best time to buy and the time of maximum optimism is the best time to sell." - John Templeton


 
"The key to making money in stocks is not to get scared out of them." - Peter Lynch

 "Only those who are asleep make no mistakes." – Ingvar Kamprad


 
"The economy depends about as much on economists as the weather does on weather forecasters." - Jean-Paul Kauffmann



 
"Literature is an investment of genius which pays dividends to all subsequent times." - John Burroughs




 Stock market bubbles don't grow out of thin air. They have a solid basis in reality, but realty as distorted by a misconception" - G. Soros



 
"Markets are constantly in a state of uncertainty and flux and $ is made by discounting the obvious and betting on the unexpected. " - Soros



 "I guess I should warn you, if I turn out to be particularly clear, you've probably misunderstood what I've said." -Alan Greenspan




 "Money couldn't buy friends, but you got a better class of enemy." - Spike Milligan


 
"The way to make money is to buy when blood is running in the streets." - John D. Rockefeller


 "If I’d only followed CNBC’s advice, I’d have a million dollars today. Provided I’d started with a hundred million dollars." -Jon Stewart


 
"Markets can remain irrational longer than you can remain solvent." -John Maynard Keynes



 
"If past history was all there was to the game, the richest people would be librarians." - Warren Buffett


 
"Diversification is a hedge for ignorance" - William O’Neil.



 
"You must not only learn to live with tension, you must seek it out. You must learn to thrive on stress." – J. Paul Getty













Sunday, March 17, 2013

Books About Investing

Top 10 Books for the New Investor, or Great Books to Read or Review for the Not-So-New Investor

Just a list of recommendations I thought I’d try and put together. It was really hard to only pick 10, but here’s one attempt at it.

1. The Intelligent Investor

2. The Essays of Warren Buffett

3. Poor Charlie's Almanack

4. The Most Important Thing Illuminated

5. Seeking Wisdom: From Darwin to Munger

6. The Investment Checklist

7. The Little Book of Behavioral Investing

8. Competition Demystified

9. Boombustology

 
 
 
 
 
1.  The Intelligent Investor: The Definitive Book on Value Investing. A Book of Practical Counsel (Revised Edition)  
 By Benjamin Graham, Jason Zweig

 

2.  The Essays of Warren Buffett: Lessons for Corporate America, Third Edition By Warren E. Buffett, Lawrence A. Cunningham

 

3. Poor Charlie's Almanack
The Wit and Wisdom of Charles T. Munger
Expanded Third Edition

Forward by Warren E. Buffett

Edited by Peter D. Kaufman

4. The Most Important Thing Illuminated: Uncommon Sense for the Thoughtful Investor (Columbia Business School Publishing)
By Howard Marks





5. Seeking Wisdom
From Darwin to Munger
Third Edition
By Peter Bevelin


 

6. The Investment Checklist: The Art of In-Depth Research
By Michael Shearn



A practical guide to making more informed investment decisions
Investors often buy or sell stocks too quickly. When you base your purchase decisions on isolated facts and don't take the time to thoroughly understand the businesses you are buying, stock-price swings and third-party opinion can lead to costly investment mistakes. Your decision making at this point becomes dangerous because it is dominated by emotions. The Investment Checklist has been designed to help you develop an in-depth research process, from generating and researching investment ideas to assessing the quality of a business and its management team.
The purpose of The Investment Checklist is to help you implement a principled investing strategy through a series of checklists. In it, a thorough and comprehensive research process is made simpler through the use of straightforward checklists that will allow you to identify quality investment opportunities. Each chapter contains detailed demonstrations of how and where to find the information necessary to answer fundamental questions about investment opportunities. Real-world examples of how investment managers and CEOs apply these universal principles are also included and help bring the concepts to life. These checklists will help you consider a fuller range of possibilities in your investment strategy, enhance your ability to value your investments by giving you a holistic view of the business and each of its moving parts, identify the risks you are taking, and much more.
  • Offers valuable insights into one of the most important aspects of successful investing, in-depth research
  • Written in an accessible style that allows aspiring investors to easily understand and apply the concepts covered
  • Discusses how to think through your investment decisions more carefully
With The Investment Checklist, you'll quickly be able to ascertain how well you understand your investments by the questions you are able to answer, or not answer, without making the costly mistakes that usually hinder other investors.





7. The Little Book of Behavioral Investing: How not to be your own worst enemy (Little Books, Big Profits (UK)) By James Montier


8. Competition Demystified: A Radically Simplified Approach to Business Strategy By Bruce C. Greenwald, Judd Kahn


9. Boombustology: Spotting Financial Bubbles Before They Burst By Vikram Mansharamani

 

10. Fooled by Randomness: The Hidden Role of Chance in Life and in the Markets
By Nassim Nicholas Taleb